PURE Bioscience Revenue Edges Up as Net Loss Narrows

PURE Bioscience reported a third-quarter GAAP loss of $0.01 per share on revenue of $0.51 million, a 4.1% increase from the same period last year. The company, which sells silver-based disinfectant technology, posted net product sales of $1.656 million for the first nine months of its fiscal year, up from $1.435 million a year earlier.

The revenue growth came entirely from the core product line. PURE's SDC technology, used in food safety and healthcare settings, has been the primary revenue driver. The company has been working to expand distribution beyond its traditional institutional customer base into retail and e-commerce channels, though those efforts have not yet produced a material shift in the sales mix.

Operating expenses for the quarter were roughly flat year-over-year, which allowed the narrower per-share loss. The company ended the period with cash and equivalents of about $2.1 million, down from $3.4 million at the start of the fiscal year. At the current burn rate, the cash position gives PURE roughly 12 to 18 months of runway before it would need to raise additional capital, based on the trailing nine-month operating cash outflow.

The stock trades on the OTC Markets under the ticker PURE. It has been below $1 for more than two years. The company has not provided forward revenue guidance in its earnings release.